What is NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial and Follow Its Development on 1stOncology

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) is a clinical trial that analyzes patients’ tumors to determine whether they contain genetic abnormalities for which a targeted drug exists (that is, "actionable mutations") and assigns treatment based on the abnormality (Company Web Page, National Cancer Institute, OCT 30, 2015, View Source [SID:1234507863]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NCI-MATCH seeks to determine whether treating cancers according to their molecular abnormalities will show evidence of effectiveness.

NCI-MATCH can add new treatments or drop treatments over time. Each treatment will be used in a unique arm, or substudy, of the trial.

The trial opened for enrollment in August 2015 with 10 arms. Each arm will enroll adults 18 years of age and older with advanced solid tumors and lymphomas that are no longer responding (or never responded) to standard therapy and have begun to grow. Additional arms are expected to open for enrollment later in 2015 and early in 2016.

NCI-MATCH investigators plan to obtain tumor biopsy specimens from as many as 3,000 patients initially. The specimens will undergo DNA sequencing to identify those that have genetic abnormalities that may respond to the targeted drugs selected for the trial. The drugs included in the trial have all either been approved by the U.S. Food and Drug Administration (FDA) for another cancer indication or are still being tested in other clinical trials but have shown some effectiveness against tumors with a particular genetic alteration(s). It is anticipated that more than 20 drugs will ultimately be tested, each in a different arm of the trial.
How NCI-MATCH Is Unique

NCI-MATCH, which is coordinated by the ECOG-ACRIN Cancer Research GroupExit Disclaimer, has national reach and is opening at clinical sites across the United States that participate in NCI’s National Clinical Trials Network. Therefore, patients may not need to travel far from home to enroll in the trial. The trial also employs the expertise of the NCI and of specialized investigators and scientists within NCI-Designated Cancer Centers and networks who are at the cutting edge of precision medicine in oncology, as well as clinical oncologist and community practices that are experienced in clinical trials, such as those that are part of the NCI Community Oncology Research Program.

NCI-MATCH uses an advanced DNA sequencing test that has been extensively validated across four certified laboratories for high consistency of results. The investigators in the chosen laboratories are among those with the most expertise in these types of assays. The trial will also use standard procedures for the collection of specimens and for preparing specimens for analysis.

The trial will have many more drugs available than most other trials. Many pharmaceutical companies are collaborating in NCI-MATCH and have also contributed their expertise.

Because it is difficult to perform molecularly targeted clinical trials except in the most prevalent types of cancer, NCI-MATCH is designed to be able to detect responses to the inhibition of driver mutations in more than one tumor type. Such findings can then be followed up with additional clinical trials to learn more about the effect of the drug on patients whose tumors have the targeted mutation.

Read more at View Source